NEW YORK (360Dx) – Swedish blood test developer AroCell announced today it will collaborate with Green Cross Cell to develop TK 210 ELISA as a complementary test for the Korean firm's therapeutic products and methods.

The agreement also gives Green Cross Cell distribution rights to the test.

The TK 210 ELISA test measures TK1 protein levels in cancer patients, potentially providing prognostic information, as well as optimizing treatment strategies.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.